Plasma cell

EQS-News: Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study

Retrieved on: 
수요일, 4월 10, 2024
Multiple myeloma, Bone marrow, Cohort, Infection, Incidence, BCMA, Patient, Plasma cell, Mortality, B cell, Spacecraft, AACR, Annual report, Antibody, The Annual Report, Safety, Pharmacokinetics, HPHA, FDA, ATAC, Food, Pharmaceutical industry

Multiple myeloma is a type of blood cancer that develops from plasma cells in the bone marrow and can affect more than one part of the body.

Key Points: 
  • Multiple myeloma is a type of blood cancer that develops from plasma cells in the bone marrow and can affect more than one part of the body.
  • Plasma cells are a type of blood cell that makes antibodies to fight infection, created by bone marrow.
  • Heidelberg Pharma’s Phase I/IIa clinical study is an ongoing, non-randomised, open label study which is actively enrolling patients with relapsed or refractory multiple myeloma or other plasma cell disorders expressing BCMA.
  • Prof. Dr. Andreas Pahl, Chief Executive Officer at Heidelberg Pharma, said: “Our proprietary ATAC candidate HDP-101 is showing exciting potential for treating multiple myeloma.

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Retrieved on: 
월요일, 11월 27, 2023
Christian democracy, Family, PDC, Antigen, B cell, Immunology, BDCA2, IND, Autoimmunity, Research, Plasma cell, SLE, Inflammation, Half-life, CD122, SAN, Lupus, GMP, CNTA, Monocyte, Patient, Antigen presentation, Therapy, Vaccine

Anaptys anticipates filing an IND application for CBS004, which will be renamed ANB101, in H2 2024.

Key Points: 
  • Anaptys anticipates filing an IND application for CBS004, which will be renamed ANB101, in H2 2024.
  • Under the terms of the agreement, Anaptys will receive from Centessa Pharmaceuticals an exclusive, global license for ANB101.
  • Anaptys will also receive the same rights to ANB102, an extended half-life BDCA2 modulator with the potential to enable quarterly or less frequent dosing.
  • Centessa is eligible to receive an additional development milestone payment and low single-digit royalties on global net sales.

Be Biopharma Study Shows First Demonstration of Rapid Engraftment of B Cells without Preconditioning in Non-Human Primates with Intact Immune Systems

Retrieved on: 
금요일, 5월 19, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Human, Gene, CD20, Engineering, National Heart, Lung, and Blood Institute, Bone marrow, PET, Therapure BioPharma Inc, Cell, PST, Lung, Plasma cell, Bangladesh Technical Education Board, NHLBI, Spleen, Patient, B cell, Annual general meeting, PET/CT, Liver, Chromium toxicity, NHP, Society, Vaccine

The study was designed to evaluate engraftment without preconditioning of ex vivo expanded NHP plasma cells.

Key Points: 
  • The study was designed to evaluate engraftment without preconditioning of ex vivo expanded NHP plasma cells.
  • Plasma cells are terminally differentiated B cells which can live for decades1 and have the capacity to secrete extremely high levels of protein2.
  • In two NHPs, B cells were collected, expanded, and differentiated into plasma cells.
  • Differentiation to plasma cells was demonstrated by loss of CD20 (protein found in B cells) along with antibody class switching (>75% Immunoglobulin G producing cells).

Be Biopharma Announces Oral Presentation on Precise Genome Engineering of Human B Cells to Express Diverse Therapeutic Proteins at American Society of Gene & Cell Therapy 26th Annual Meeting

Retrieved on: 
목요일, 5월 18, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, CRISPR, SMPD1, Factor IX, Gene, Acute lymphoblastic leukemia, ALL, Seattle, Engineering, Bone marrow, Cancer, ASM, Therapure BioPharma Inc, FIX, HDR, PST, AAV, Plasma cell, Plasma, Protein, Transgene, Spleen, Patient, Risk, Haemophilia, Flow cytometry, Annual general meeting, Cell, CCR5, Notifiable disease, Phenotype, Society, PCR, Disease, Vaccine, NPD

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BeCMs), will present preclinical research today showing the precise genome engineering of human B cells to express diverse therapeutic proteins using the company’s proprietary platform.

Key Points: 
  • Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BeCMs), will present preclinical research today showing the precise genome engineering of human B cells to express diverse therapeutic proteins using the company’s proprietary platform.
  • The findings will be presented during an oral session at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting at 2:15-2:30 p.m. PST with additional data in poster presentation 1453 on Friday, May 19th from 12:00-2:00 p.m. PST.
  • However, it has historically been challenging to genetically engineer B cells efficiently, precisely, and in a manner that could produce proteins at therapeutic levels over long durations.
  • These fundamental platform attributes overcome historical challenges for scalable and effective B cell engineering.

FORUS Therapeutics Inc ("FORUS") Announces XPOVIO® (selinexor) Is Authorized for Sale by Health Canada

Retrieved on: 
화요일, 6월 7, 2022
MM, Life, Oncology, Caregiver, Adult, Multiple myeloma, Radical behaviorism, Lymphatic system, CEO, Professor, Disease, Plasma cell, Solution, Physician, Sale, Tumor suppressor gene, Therapy, Growth, Bortezomib, Master of Science, Health Canada, Myeloma Canada, Patient, Program, B cell, XPO1, Immune system, Antibody, SINE, Dexamethasone, Department, Princess Margaret Cancer Centre, Bone marrow, Hematology, Cancer, Pharmaceutical industry

This is the first regulatory approval for XPOVIO in Canada in multiple myeloma and follows recent approvals in Australia, China, South Korea, Singapore and the United States.

Key Points: 
  • This is the first regulatory approval for XPOVIO in Canada in multiple myeloma and follows recent approvals in Australia, China, South Korea, Singapore and the United States.
  • "The FORUS team is very proud to launch XPOVIO in Canada and bring forth a novel and effective addition to existing regimens for the treatment of relapsed or refractory multiple myeloma.
  • XPOVIO is a registered trademark of Karyopharm Therapeutics Inc. and is used by FORUS Therapeutics Inc. under license.
  • FORUS Therapeutics is a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer.

Global Multiple Myeloma Treatment Market (2021 to 2026) - Key Drivers, Challenges and Opportunities - ResearchAndMarkets.com

Retrieved on: 
화요일, 5월 11, 2021
Pharmaceutical, Health, Oncology, Medical specialties, Branches of biology, Medicine, Immune system, Multiple myeloma, Myeloma protein, Immunology, Plasma cell, Monoclonal gammopathy of undetermined significance, Smouldering myeloma

b'The "Multiple Myeloma Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com\'s offering.\nThis report offers strategic insights into the overall multiple myeloma treatment market along with the market size and estimates for the duration 2019 to 2029.

Key Points: 
  • b'The "Multiple Myeloma Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com\'s offering.\nThis report offers strategic insights into the overall multiple myeloma treatment market along with the market size and estimates for the duration 2019 to 2029.
  • The said research study cover in-depth analysis of multiple myeloma market segments based on type and different geographies further segmented by countries.
  • According to myeloma UK, in myeloma, plasma cells become abnormal, multiply uncontrollably and release only one type of antibody known as paraprotein, which has no useful function.
  • It is often through the measurement of this paraprotein that myeloma is diagnosed and monitored.\nFor the purpose of this study, the global multiple myeloma treatment market is segmented on the basis of type into Drug Therapy, Stem cell Transplantation, Biophosphonates, Radiation Therapy, & Surgical Therapy.

Global Multiple Myeloma Disease Coverage Forecast and Market Analysis 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
금요일, 4월 9, 2021
Health, Stem cells, Pharmaceutical, Clinical trials, Oncology, Medical specialties, Branches of biology, Clinical medicine, Stem cells, Hematology, Multiple myeloma, Immune system, Bone marrow, Hematopoietic stem cell transplantation, Plasma cell, Smouldering myeloma, Waldenström's macroglobulinemia

The "Multiple Myeloma Disease Coverage Forecast and Market Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Multiple Myeloma Disease Coverage Forecast and Market Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Multiple myeloma is characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow.
  • Most patients will receive at least three lines of treatment, and eligible patients will receive stem cell transplantation.
  • MM drugs, on average, take 9.0 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

Outlook on the Multiple Myeloma Drugs Global Market to 2025 - by Therapy, Drug Type, End-user, Distribution Channel and Region - ResearchAndMarkets.com

Retrieved on: 
금요일, 12월 4, 2020
Pharmaceutical, Health, Oncology, Medicine, Clinical medicine, Branches of biology, Oncology, Multiple myeloma, Antineoplastic drugs, Immune system, Chemotherapy, Kahler, Plasma cell, Daratumumab, Smouldering myeloma

The "Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • The global multiple myeloma drugs market grew at a CAGR of around 9% during 2014-2019.
  • Multiple myeloma, or Kahler's disease, refers to a form of blood cancer that primarily affects the plasma cells.
  • Some of the most common types of multiple myeloma drugs include chemotherapeutic agents, corticosteroids and immunomodulatory agents.

Global Multiple Myeloma Disease Coverage Forecast and Market Analysis 2018-2027

Retrieved on: 
월요일, 10월 19, 2020
Branches of biology, Medical specialties, Medicine, Immune system, Multiple myeloma, RTT, Plasma cell, Bone marrow, Targeted therapy, Serum B-cell maturation antigen, Smouldering myeloma

DUBLIN, Oct. 19, 2020 /PRNewswire/ -- The "Multiple Myeloma Disease Coverage Forecast and Market Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 19, 2020 /PRNewswire/ -- The "Multiple Myeloma Disease Coverage Forecast and Market Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Multiple myeloma is characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow.
  • The launch of BCMA-targeted therapies will play a pivotal part in future market dynamics over the next decade.
  • These drugs have broad approvals across all markets, and the expected expiry of their patents will exert substantial downward pressure on the MM market.

First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma

Retrieved on: 
화요일, 10월 6, 2020
Medical specialties, Branches of biology, Clinical medicine, Immune system, Immunology, Multiple myeloma, RTT, Plasma cell, T cell, Plasma cell dyscrasias, Smouldering myeloma

NEXI-002 is a patient-derived cellular product that contains populations of naturally-occurring CD8+ T cells directed against several multiple myeloma (MM)-specific antigen targets.

Key Points: 
  • NEXI-002 is a patient-derived cellular product that contains populations of naturally-occurring CD8+ T cells directed against several multiple myeloma (MM)-specific antigen targets.
  • We believe this approach has potential to address primary tumor escape mechanisms, and provide deep and durable clinical responses.
  • According to the Multiple Myeloma Research Foundation, multiple myeloma is a type of blood cancer that affects plasma cells.
  • In multiple myeloma, malignant plasma cells accumulate in the bone marrow, crowding out the normal plasma cells that help fight infection.